Chemistry:GSK 299423

From HandWiki
GSK 299423
GSK 299423.png
GSK299423 3D 2XCS.png
Names
Preferred IUPAC name
6-Methoxy-4-[2-(4-{[(2H-[1,3]oxathiolo[5,4-c]pyridin-6-yl)methyl]amino}piperidin-1-yl)ethyl]quinoline-3-carbonitrile
Identifiers
3D model (JSmol)
ChemSpider
UNII
Properties
C25H27N5O2S
Molar mass 461.58 g·mol−1
Except where otherwise noted, data are given for materials in their standard state (at 25 °C [77 °F], 100 kPa).
☒N verify (what is ☑Y☒N ?)
Infobox references
3D protein map of GSK 299423 (yellow) in complex with Staphylococcus aureus DNA gyrase (teal) and a DNA fragment (orange). From PDB: 2xcs​.

GSK 299423 or GlaxoSmithKline 299423 is an antibiotic chemical compound that has been identified as potentially effective in treating patients infected with bacteria expressing the New Delhi metallo-beta-lactamase. The antibiotic inhibits the enzyme topoisomerase, which bacteria need to replicate.[1][2][3]

No animal studies have been reported. No application has been made for human clinical trials.[citation needed]

References

  1. Sten Stovall, "Glaxo:New Compound Offers Way To Fight Drug-Resistant Bacteria[yes|permanent dead link|dead link}}]," The Wall Street Journal , August 4, 2010
  2. Melly Alazraki, "GlaxoSmithKline Finds Compound That Could Help Fight 'Superbugs' " Daily Finance, August 6, 2010
  3. "Type IIA topoisomerase inhibition by a new class of antibacterial agents". Nature 466 (7309): 935–40. 4 August 2010. doi:10.1038/nature09197. PMID 20686482. Bibcode2010Natur.466..935B.  (primary source)